JP2003526628A5 - - Google Patents

Download PDF

Info

Publication number
JP2003526628A5
JP2003526628A5 JP2001517689A JP2001517689A JP2003526628A5 JP 2003526628 A5 JP2003526628 A5 JP 2003526628A5 JP 2001517689 A JP2001517689 A JP 2001517689A JP 2001517689 A JP2001517689 A JP 2001517689A JP 2003526628 A5 JP2003526628 A5 JP 2003526628A5
Authority
JP
Japan
Prior art keywords
nucleoside
cpg dinucleotide
cpg
oligonucleotide
dinucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001517689A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003526628A (ja
JP5268214B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/022284 external-priority patent/WO2001012804A2/en
Publication of JP2003526628A publication Critical patent/JP2003526628A/ja
Publication of JP2003526628A5 publication Critical patent/JP2003526628A5/ja
Application granted granted Critical
Publication of JP5268214B2 publication Critical patent/JP5268214B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001517689A 1999-08-13 2000-08-14 ヌクレオシドの位置的修飾によるオリゴヌクレオチドCpG−媒体免疫刺激の変調 Expired - Fee Related JP5268214B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14879899P 1999-08-13 1999-08-13
US60/148,798 1999-08-13
PCT/US2000/022284 WO2001012804A2 (en) 1999-08-13 2000-08-14 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010212544A Division JP2011019527A (ja) 1999-08-13 2010-09-22 ヌクレオシドの位置的修飾によるオリゴヌクレオチドCpG−媒体免疫刺激の変調

Publications (3)

Publication Number Publication Date
JP2003526628A JP2003526628A (ja) 2003-09-09
JP2003526628A5 true JP2003526628A5 (https=) 2006-01-05
JP5268214B2 JP5268214B2 (ja) 2013-08-21

Family

ID=22527436

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001517689A Expired - Fee Related JP5268214B2 (ja) 1999-08-13 2000-08-14 ヌクレオシドの位置的修飾によるオリゴヌクレオチドCpG−媒体免疫刺激の変調
JP2010212544A Pending JP2011019527A (ja) 1999-08-13 2010-09-22 ヌクレオシドの位置的修飾によるオリゴヌクレオチドCpG−媒体免疫刺激の変調

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010212544A Pending JP2011019527A (ja) 1999-08-13 2010-09-22 ヌクレオシドの位置的修飾によるオリゴヌクレオチドCpG−媒体免疫刺激の変調

Country Status (13)

Country Link
US (1) US6476000B1 (https=)
EP (2) EP2314693A3 (https=)
JP (2) JP5268214B2 (https=)
KR (1) KR100651294B1 (https=)
AT (1) ATE286534T1 (https=)
AU (2) AU783745B2 (https=)
CA (2) CA2784789A1 (https=)
DE (1) DE60017259T2 (https=)
DK (1) DK1200580T3 (https=)
ES (1) ES2233426T3 (https=)
MX (1) MXPA02001610A (https=)
PT (1) PT1200580E (https=)
WO (1) WO2001012804A2 (https=)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
AU2001227889A1 (en) 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
AU5736601A (en) 2000-05-01 2001-11-12 Hybridon Inc Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
EP1850850A4 (en) * 2000-12-08 2011-06-15 3M Innovative Properties Co COMPOSITIONS AND METHOD FOR TARGETED ADMINISTRATION OF IMMUNE RESPONSE MODIFICATORS
US7105495B2 (en) 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7176296B2 (en) 2001-04-30 2007-02-13 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
EP2423335B1 (en) * 2001-06-21 2014-05-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
US20030133988A1 (en) * 2001-08-07 2003-07-17 Fearon Karen L. Immunomodulatory compositions, formulations, and methods for use thereof
WO2003020884A2 (en) 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
EP1455700A4 (en) * 2001-11-16 2007-02-14 3M Innovative Properties Co METHODS AND COMPOSITIONS RELATED TO MRI COMPOUNDS AND TO TOLL-TYPE RECEPTOR (TLR) PATHWAYS
WO2003054161A2 (en) 2001-12-20 2003-07-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
WO2003066649A1 (en) 2002-02-04 2003-08-14 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
HUE025145T2 (en) * 2002-02-22 2016-01-28 Meda Ab A method for reducing and treating immunosuppression induced by ultraviolet B radiation
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
DK1545597T3 (da) 2002-08-15 2011-01-31 3M Innovative Properties Co Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
WO2004053057A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
JP5102959B2 (ja) * 2002-12-23 2012-12-19 ダイナバックス テクノロジーズ コーポレイション 免疫刺激配列オリゴヌクレオチド及びその使用方法
EP2572714A1 (en) * 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
CA2512484A1 (en) 2003-01-16 2004-05-08 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
JP2006517974A (ja) * 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Irm化合物およびトル様受容体8に関する方法および組成物
WO2004074454A2 (en) 2003-02-20 2004-09-02 University Of Connecticut Health Center Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
EP1599726A4 (en) * 2003-02-27 2009-07-22 3M Innovative Properties Co SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
KR100681470B1 (ko) * 2003-03-03 2007-02-12 연세대학교 산학협력단 면역반응 증진용 올리고뉴크레오타이드
JP2006519866A (ja) 2003-03-04 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー Uv誘発性の表皮の新形成の予防的治療
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
KR20050109562A (ko) * 2003-03-13 2005-11-21 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피부의 질을 개선시키는 방법
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
EP1615665A4 (en) * 2003-04-10 2010-10-06 3M Innovative Properties Co DISTRIBUTION OF THE IMMUNE RESPONSE MODIFYING LINKS
MXPA05012421A (es) 2003-05-16 2006-02-22 Hybridon Inc Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.
MXPA06000619A (es) * 2003-07-15 2006-04-11 Hybridon Inc Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
US20080039533A1 (en) * 2003-07-31 2008-02-14 3M Innovative Properties Company Bioactive Compositions Comprising Triazines
CN1852711A (zh) * 2003-08-05 2006-10-25 3M创新有限公司 使用免疫响应调节化合物的传染病预防
BRPI0413558A (pt) 2003-08-12 2006-10-17 3M Innovative Properties Co compostos contendo imidazo substituìdo por hidroxilamina
US8961477B2 (en) 2003-08-25 2015-02-24 3M Innovative Properties Company Delivery of immune response modifier compounds
JP2007504145A (ja) * 2003-08-25 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー 免疫刺激性の組み合わせおよび治療
AU2004268625B2 (en) 2003-08-27 2011-03-31 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
EP1663222A4 (en) * 2003-09-02 2008-05-21 3M Innovative Properties Co METHODS RELATING TO THE TREATMENT OF GIANCES
AU2004270201A1 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
AU2004275876B2 (en) 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
AR046046A1 (es) 2003-10-03 2005-11-23 3M Innovative Properties Co Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
EP1678303A2 (en) 2003-10-30 2006-07-12 Coley Pharmaceutical GmbH C-class oligonucleotide analogs with enhanced immunostimulatory potency
JP2007509987A (ja) * 2003-10-31 2007-04-19 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤化合物による好中球活性化
EP1685129A4 (en) 2003-11-14 2008-10-22 3M Innovative Properties Co OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
CA2545825A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
CA2547020C (en) 2003-11-25 2014-03-25 3M Innovative Properties Company 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
US8940755B2 (en) * 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
CA2549173A1 (en) 2003-12-08 2005-07-07 Hybridon, Inc. Modulation of immunostimulatory properties by small oligonucleotide-based compounds
JP2007517035A (ja) 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
US20050239735A1 (en) * 2003-12-30 2005-10-27 3M Innovative Properties Company Enhancement of immune responses
EP1699788A2 (en) 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides
WO2005094531A2 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
MXPA06012451A (es) * 2004-04-28 2007-01-31 3M Innovative Properties Co Composiciones y metodos para vacunacion por la mucosa.
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
US20080154210A1 (en) 2004-05-28 2008-06-26 Oryxe Mixture for Transdermal Delivery of Low and High Molecular Weight Compounds
US20080113929A1 (en) * 2004-06-08 2008-05-15 Coley Pharmaceutical Gmbh Abasic Oligonucleotide as Carrier Platform for Antigen and Immunostimulatory Agonist and Antagonist
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006026470A2 (en) * 2004-08-27 2006-03-09 3M Innovative Properties Company Hiv immunostimulatory compositions
EP1804583A4 (en) * 2004-10-08 2009-05-20 3M Innovative Properties Co ADJUVANT FOR DNA VACCINE
JP5543068B2 (ja) 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー キラル縮合[1,2]イミダゾ[4,5−c]環状化合物
EP1831221B1 (en) 2004-12-30 2012-08-08 3M Innovative Properties Company Substituted chiral fused 1,2 imidazo 4,5-c ring compounds
PL1830876T3 (pl) 2004-12-30 2015-09-30 Meda Ab Zastosowanie imikwimodu do leczenia przerzutów do skóry wywodzących się od guza stanowiącego raka piersi
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
AU2006213746A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
EP2982679A1 (en) 2005-10-12 2016-02-10 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
EP2371956A3 (en) 2005-11-07 2012-01-04 Idera Pharmaceuticals Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
US7776834B2 (en) * 2005-11-07 2010-08-17 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
PT2078080E (pt) 2006-09-27 2015-09-18 Coley Pharm Gmbh Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
JP2010536787A (ja) * 2007-08-15 2010-12-02 イデラ ファーマシューティカルズ インコーポレイテッド Toll様受容体モジュレータ
WO2010042543A2 (en) * 2008-10-06 2010-04-15 Idera Pharmaceuticals, Inc. Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto
EP2451974A2 (en) * 2009-07-08 2012-05-16 Idera Pharmaceuticals, Inc. Oligonucleotide-based compounds as inhibitors of toll-like receptors
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
JP5813778B2 (ja) 2010-11-19 2015-11-17 イデラ ファーマシューティカルズ インコーポレイテッドIdera Pharmaceuticals, Inc. トール様受容体に基づく免疫反応を調節するための免疫調節オリゴヌクレオチド(iro)化合物
JP6460789B2 (ja) 2011-06-03 2019-01-30 スリーエム イノベイティブ プロパティズ カンパニー ポリエチレングリコールセグメントを有するヘテロ2官能性リンカー及び該リンカーから調製された免疫反応調節複合体
BR112013031039B1 (pt) 2011-06-03 2020-04-28 3M Innovative Properties Co compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
ES3020582T3 (en) 2013-07-26 2025-05-23 Inst Nat Sante Rech Med Methods and pharmaceutical compositions for the treatment of bacterial infections
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
US11260018B2 (en) 2015-09-17 2022-03-01 Jrx Biotechnology, Inc. Approaches for improving skin hydration and moisturization
RU2730871C1 (ru) * 2015-09-30 2020-08-26 Сионоги Энд Ко., Лтд. Производное нуклеиновой кислоты, обладающее иммуностимулирующей активностью
US10940201B2 (en) 2015-09-30 2021-03-09 Shionogi & Co., Ltd. Nucleic acid derivative having immunostimulatory activity
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
MX2019002925A (es) 2016-09-15 2019-09-05 Idera Pharmaceuticals Inc Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.
SG11201908059YA (en) * 2017-03-29 2019-10-30 Shionogi & Co Nucleic acid derivative having immunostimulatory activity
AU2019228381B2 (en) 2018-02-28 2021-12-16 Pfizer Inc. IL-15 variants and uses thereof
MX2020012607A (es) 2018-05-23 2021-01-29 Pfizer Anticuerpos especificos para gucy2c y sus usos.
KR102602329B1 (ko) 2018-05-23 2023-11-16 화이자 인코포레이티드 Cd3에 특이적인 항체 및 이의 용도
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
CA3164623A1 (en) 2019-12-17 2021-06-24 Pfizer Inc. Antibodies specific for cd47, pd-l1, and uses thereof
MX2023000662A (es) 2020-07-17 2023-02-27 Pfizer Anticuerpos terapeuticos y sus usos.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149798A (en) 1989-04-06 1992-09-22 Worcester Foundation For Experimental Biology Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses
US6153595A (en) * 1990-08-16 2000-11-28 Isis Pharmaceuticals Inc. Composition and method for treatment of CMV infections
WO1993013114A1 (en) * 1991-12-24 1993-07-08 Isis Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR MODULATING β-AMYLOID
US6235723B1 (en) * 1992-03-16 2001-05-22 Isis Pharmaceuticals , Inc. Antisense oligonucleotide modulation of human protein kinase C-δ expression
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5591721A (en) * 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5968909A (en) * 1995-08-04 1999-10-19 Hybridon, Inc. Method of modulating gene expression with reduced immunostimulatory response
US5652356A (en) * 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5886165A (en) * 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
ES2255732T3 (es) * 1997-08-19 2006-07-01 Idera Pharmaceuticals, Inc. Oligonucleotidos especificos de vih y procedimientos para su utilizacion.
US6228642B1 (en) * 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression

Similar Documents

Publication Publication Date Title
JP2003526628A5 (https=)
Rayburn et al. Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?
JP5268214B2 (ja) ヌクレオシドの位置的修飾によるオリゴヌクレオチドCpG−媒体免疫刺激の変調
US7045609B2 (en) Hybrid oligonucleotide phosphorothioates
DE60109916T2 (de) MODULATION EINER OLIGONUKLEOTID- CpG-VERMITTELTEN IMMUNSTIMULATION DURCH POSITIONELLE MODIFIKATION VON NUKLEOSIDEN
US5652355A (en) Hybrid oligonucleotide phosphorothioates
US6143881A (en) Hybrid oligonucleotide phosphorothioates
JP2006502694A5 (https=)
EP0649467A1 (en) Self-stabilized oligonucleotides as therapeutic agents
RU2004132209A (ru) Иммуностимулирующие g, u-содержащие олигорибонуклеотиды
JP2001501614A (ja) 三つの構成成分からなるキメラアンチセンスオリゴヌクレオチド
CA2526831A1 (en) Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
RU2010112771A (ru) Иммуностимулирующие аналоги олигонуклеотидов, содержащие модифицированные сахарные группировки
Volkmann et al. Inhibition of HIV-1 reverse transcription by triple-helix forming oligonucleotides with viral RNA
AU2001284570B2 (en) New sequences
Ecker et al. Novel guanosine quartet structure binds to the HIV envelope and inhibits envelope mediated cell fusion
Praseuth et al. Unexpected effect of an anti-human immunodeficiency virus intermolecular triplex-forming oligonucleotide in an in vitro transcription system due to RNase H-induced cleavage of the RNA transcript
Cohen History of research on antisense oligonucleotide analogs
AU2001284570A1 (en) New sequences
Behlke et al. Designing antisense oligonucleotides
AU2005218065B2 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
Matthes et al. Potent inhibitory activity of chimeric oligonucleotides targeting two different sites of human telomerase
Galderisi et al. Antisense oligonucleotides as drugs for HIV treatment
Zamaratski Some Aspects of Nucleic Acids Chemistry